ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 199 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,080 | -18.4% | 40,948 | -6.0% | 0.01% | -16.7% |
| Q1 2024 | $1,323 | +5.9% | 43,562 | -2.0% | 0.01% | 0.0% |
| Q4 2023 | $1,249 | -19.1% | 44,450 | -21.9% | 0.01% | +50.0% |
| Q3 2023 | $1,543 | +12.3% | 56,891 | +27.3% | 0.00% | -42.9% |
| Q2 2023 | $1,374 | -14.7% | 44,696 | 0.0% | 0.01% | -12.5% |
| Q1 2023 | $1,610 | -8.8% | 44,696 | 0.0% | 0.01% | -20.0% |
| Q4 2022 | $1,766 | -99.9% | 44,696 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $1,796,000 | -4.4% | 44,696 | 0.0% | 0.01% | 0.0% |
| Q2 2022 | $1,879,000 | +7.9% | 44,696 | 0.0% | 0.01% | +25.0% |
| Q1 2022 | $1,741,000 | -8.4% | 44,696 | -6.3% | 0.01% | 0.0% |
| Q4 2021 | $1,901,000 | +210.6% | 47,709 | +181.6% | 0.01% | +166.7% |
| Q3 2021 | $612,000 | -11.9% | 16,944 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $695,000 | -6.0% | 16,944 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $739,000 | -12.9% | 16,944 | 0.0% | 0.00% | -25.0% |
| Q4 2020 | $848,000 | – | 16,944 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $263,446,000 | 59.92% |
| Memorial Sloan Kettering Cancer Center | 1,128,255 | $43,957,000 | 50.90% |
| Vantage Consulting Group Inc | 2,727,854 | $106,277,000 | 41.47% |
| Indie Asset Partners, LLC | 756,874 | $29,488,000 | 22.15% |
| Overbrook Management Corp | 723,250 | $28,178,000 | 6.25% |
| Brown University | 621,759 | $24,224,000 | 5.93% |
| Geo Capital Gestora de Recursos Ltd | 200,692 | $8,527,000 | 3.82% |
| Lagoda Investment Management, L.P. | 141,560 | $5,515,000 | 2.97% |
| Greytown Advisors Inc. | 131,143 | $5,109,000 | 2.47% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,025,610 | $78,918,000 | 2.41% |